1. Home
  2. KNSA vs KYN Comparison

KNSA vs KYN Comparison

Compare KNSA & KYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KNSA
  • KYN
  • Stock Information
  • Founded
  • KNSA 2015
  • KYN 2004
  • Country
  • KNSA United Kingdom
  • KYN United States
  • Employees
  • KNSA N/A
  • KYN N/A
  • Industry
  • KNSA Biotechnology: Pharmaceutical Preparations
  • KYN Finance/Investors Services
  • Sector
  • KNSA Health Care
  • KYN Finance
  • Exchange
  • KNSA Nasdaq
  • KYN Nasdaq
  • Market Cap
  • KNSA 2.0B
  • KYN 2.0B
  • IPO Year
  • KNSA 2018
  • KYN N/A
  • Fundamental
  • Price
  • KNSA $26.03
  • KYN $12.15
  • Analyst Decision
  • KNSA Strong Buy
  • KYN
  • Analyst Count
  • KNSA 6
  • KYN 0
  • Target Price
  • KNSA $38.00
  • KYN N/A
  • AVG Volume (30 Days)
  • KNSA 677.6K
  • KYN 561.5K
  • Earning Date
  • KNSA 04-29-2025
  • KYN 01-01-0001
  • Dividend Yield
  • KNSA N/A
  • KYN 8.99%
  • EPS Growth
  • KNSA N/A
  • KYN N/A
  • EPS
  • KNSA N/A
  • KYN 0.71
  • Revenue
  • KNSA $481,166,000.00
  • KYN N/A
  • Revenue This Year
  • KNSA $37.21
  • KYN N/A
  • Revenue Next Year
  • KNSA $1.53
  • KYN N/A
  • P/E Ratio
  • KNSA N/A
  • KYN $13.79
  • Revenue Growth
  • KNSA 59.45
  • KYN N/A
  • 52 Week Low
  • KNSA $17.38
  • KYN $7.84
  • 52 Week High
  • KNSA $28.56
  • KYN $9.88
  • Technical
  • Relative Strength Index (RSI)
  • KNSA 63.21
  • KYN 55.45
  • Support Level
  • KNSA $25.97
  • KYN $11.67
  • Resistance Level
  • KNSA $28.56
  • KYN $12.04
  • Average True Range (ATR)
  • KNSA 1.24
  • KYN 0.25
  • MACD
  • KNSA 0.36
  • KYN 0.07
  • Stochastic Oscillator
  • KNSA 71.70
  • KYN 92.86

About KNSA Kiniksa Pharmaceuticals Ltd.

Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.

About KYN Kayne Anderson Energy Infrastructure Fund Inc.

Kayne Anderson Energy Infrastructure Fund, Inc is a non-diversified, closed-end fund. Its investment objective is to provide a high after-tax total return with an emphasis on making cash distributions to the stockholder. The Company invests in various sectors, which include midstream energy companies, renewable infrastructure companies, and utility companies. The company seeks to achieve its objectives by investing a majority of its total assets in the securities of Energy Infrastructure companies.

Share on Social Networks: